Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives $54.63 Average PT from Analysts

Maze Therapeutics, Inc. (NASDAQ:MAZE) has received a consensus recommendation of “Buy” from the eleven brokerages that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have given a buy rating and three have issued a strong buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $58.5556.

Several analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Wedbush upped their price target on Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research note on Monday, March 16th. BTIG Research reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research note on Monday, March 9th. Mizuho raised Maze Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 11th. Finally, Truist Financial initiated coverage on Maze Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $68.00 price target on the stock.

Insider Transactions at Maze Therapeutics

In related news, SVP Amy Bachrodt sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $40.58, for a total transaction of $405,800.00. Following the completion of the transaction, the senior vice president owned 12,965 shares in the company, valued at approximately $526,119.70. The trade was a 43.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Atul Dandekar sold 72,400 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the completion of the sale, the insider directly owned 10,503 shares of the company’s stock, valued at $426,001.68. The trade was a 87.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 245,000 shares of company stock worth $10,504,792.

Hedge Funds Weigh In On Maze Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC raised its stake in Maze Therapeutics by 318.0% during the 4th quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after buying an additional 2,390,713 shares during the period. Vanguard Group Inc. grew its stake in Maze Therapeutics by 218.1% in the third quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock valued at $34,615,000 after acquiring an additional 915,342 shares during the period. Marshall Wace LLP increased its holdings in shares of Maze Therapeutics by 3,868.5% in the third quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock worth $20,166,000 after acquiring an additional 758,104 shares in the last quarter. Caligan Partners LP bought a new stake in shares of Maze Therapeutics in the fourth quarter worth about $22,794,000. Finally, ArrowMark Colorado Holdings LLC acquired a new stake in shares of Maze Therapeutics during the third quarter worth about $14,135,000.

Maze Therapeutics Stock Down 2.8%

Shares of MAZE opened at $48.03 on Friday. The stock’s 50-day moving average price is $45.84 and its 200 day moving average price is $36.97. The firm has a market capitalization of $2.31 billion, a price-to-earnings ratio of -2.30 and a beta of 4.47. Maze Therapeutics has a 12-month low of $6.71 and a 12-month high of $53.65.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.